Guideline Recommendations for Management of Low Back Pain

Acute Low Back Pain (≤ 4 weeks)

• Prioritize non‑pharmacologic therapies—superficial heat, massage, acupuncture, or spinal manipulation—before offering medication, and add NSAIDs or skeletal muscle relaxants only if the patient explicitly requests them (strong recommendation; moderate‑ to low‑quality evidence) 1, 2, 3.
• Apply superficial heat (heating pads or blankets) as first‑line non‑pharmacologic treatment (moderate‑quality evidence) 1, 2.
• Massage therapy may be offered (low‑quality evidence) 1, 2.
• Acupuncture may be offered (low‑quality evidence) 1, 2.
• Spinal manipulation performed by appropriately trained providers may be offered (low‑quality evidence) 1, 2, 4.
• If medication is requested, NSAIDs are preferred and provide roughly 10 mm greater pain relief on a 100‑mm visual analogue scale compared with acetaminophen (moderate‑quality evidence) 1.
• Acetaminophen (up to 3–4 g/day) is an alternative with a more favorable safety profile but slightly less analgesic effect (moderate‑quality evidence) 1.
• Skeletal muscle relaxants are an option (moderate‑quality evidence) 1, 2.
• Exercise therapy and supervised home‑exercise programs are not effective for acute pain (moderate‑quality evidence) 4.
• Systemic corticosteroids are ineffective and should not be used (moderate‑quality evidence) 4.

Sub‑Acute Low Back Pain (4–12 weeks)

• Intensive interdisciplinary rehabilitation provides moderate benefit and should be considered (moderate‑quality evidence) 4.
• Functional restoration programs that include a cognitive‑behavioral component reduce work absenteeism in occupational settings (moderate‑quality evidence) 4.

Chronic Low Back Pain (> 12 weeks)

First‑Line Non‑Pharmacologic Therapies (strong recommendation)

• Exercise therapy (moderate‑quality evidence) 1, 2, 3.
• Multidisciplinary rehabilitation (moderate‑quality evidence) 1, 2.
• Acupuncture (moderate‑quality evidence) 1, 2.
• Mindfulness‑based stress reduction (moderate‑quality evidence) 1, 2.
• Tai chi (low‑quality evidence) 1, 2.
• Yoga (low‑quality evidence) 1, 2.
• Motor‑control exercise (low‑quality evidence) 1, 2.
• Progressive relaxation (low‑quality evidence) 1, 2.
• Cognitive‑behavioral therapy (low‑quality evidence) 1, 2.
• Spinal manipulation (low‑quality evidence) 1, 2.
• Massage therapy (low‑quality evidence) 4.

Pharmacologic Escalation (when non‑pharmacologic therapy is insufficient)

• Tricyclic antidepressants may be used for pain relief in patients without contraindications (moderate‑quality evidence) 4.
• Gabapentin offers small, short‑term benefit for radiculopathy (moderate‑quality evidence) 4.
• Selective serotonin reuptake inhibitors and trazodone have not shown efficacy for low back pain (moderate‑quality evidence) 4.
• Benzodiazepines have similar short‑term analgesic effect to skeletal muscle relaxants but carry higher risk of abuse, addiction, and tolerance; limit to short courses (moderate‑quality evidence) 4.

Safety Considerations for Specific Medications

• Tizanidine carries a black‑box warning for potentially fatal hepatotoxicity (moderate‑quality evidence) 4.
• Chlorzoxazone is associated with generally reversible hepatotoxicity (moderate‑quality evidence) 4.
• Evidence on long‑term use of any medication for low back pain is limited; extended courses should be reserved for patients who demonstrate clear continued benefit without major adverse events (moderate‑quality evidence) 4.

Opioid Use Policy

• Opioids should not be prescribed as first‑line therapy for low back pain; they are reserved only after failure of all other recommended treatments (weak recommendation; moderate‑quality evidence) 1, 2, 3.

Management of Low Back Pain

Introduction to Low Back Pain Management

• The American College of Physicians recommends that patients with acute low back pain be reassured that 90% of episodes resolve within 6 weeks regardless of treatment, and emphasize that staying active and continuing normal activities within pain limits is more effective than bed rest for recovery 5, 6, 7
• Most patients experience rapid improvement in pain, disability, and ability to return to work within the first month, with the majority achieving substantial recovery by 6 weeks 5, 6

Activity and Self-Care Recommendations

• Patients must remain active and continue ordinary activities within the limits permitted by pain—this is a strong recommendation based on moderate-quality evidence 5, 6, 7
• Bed rest should be explicitly avoided as it is associated with increased disability and worse outcomes 5
• Apply superficial heat using heating pads or heated blankets for short-term pain relief in acute low back pain 6, 8, 7
• Use a medium-firm mattress rather than a firm mattress, as firm mattresses are less likely to lead to improvement 9, 10

Red Flags and Further Care

• Severe or progressive neurologic deficits (weakness, numbness, loss of bowel/bladder control) require immediate medical attention 5, 7
• Suspicion of serious underlying conditions such as cancer, infection, or spinal fracture requires immediate medical attention 5

Psychosocial Factors and Treatment Expectations

• Assess and address psychosocial risk factors that predict chronic disabling back pain, including depression, anxiety, job dissatisfaction, and fear-avoidance beliefs 5, 7
• Depression commonly coexists with chronic back pain and should be screened for and treated appropriately 7
• Exercise therapy is a cornerstone of treatment for chronic low back pain, with moderate evidence of efficacy 6, 8, 7

Pharmacologic Options

• For acute pain requiring medication, acetaminophen (up to 3000mg/day) or NSAIDs like ibuprofen are first-line options 5, 6, 7
• Acetaminophen has a more favorable safety profile but is slightly less effective than NSAIDs for pain relief 5, 9

Common Pitfalls to Avoid

• Do not pursue routine imaging (X-rays, MRI, CT) for nonspecific low back pain without red flags, as findings are often nonspecific and do not improve outcomes 5, 7
• Systemic corticosteroids should be avoided as they have not shown greater efficacy than placebo 7, 10